Hengrui Pharma profits jump 22% as innovative drug sales and global pivot accelerate
Compartilhar
Hengrui Pharmaceuticals delivered a high-growth start to 2026, underscored by a deepening shift toward its innovative drug portfolio and a successful entry into the U.S. capital markets.
